Every 424B that Annovis Bio, Inc. (ANVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ANVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANVS filings page.
Annovis Bio, Inc. is conducting a registered offering of 7,895,000 shares of common stock, each sold with nine-tenths of a warrant, at a combined public offering price of $1.90 per share and accompanying warrant.
The offering includes warrants to purchase up to 7,105,500 shares with a six-year term and a $2.25 exercise price; delivery is expected on or about May 21, 2026. The company estimates net proceeds of approximately $13.8M (assuming no warrant exercises) and states cash and cash equivalents of $14.2M as of March 31, 2026, which it believes funds operations into the fourth quarter of 2026. The prospectus supplement also discloses existing outstanding warrants, stock options and reserved shares that could dilute holders if exercised.
Annovis Bio is offering common stock together with detachable warrants pursuant to this prospectus supplement to its Form S-3 shelf registration. The supplement discloses underwriting arrangements with Canaccord and reiterates that the exact number of shares offered in this supplement is presented in the prospectus language but left blank in the excerpt.
The company reported $14.2M cash as of March 31, 2026, an accumulated deficit of $181.3M, and 34,646,868 shares outstanding as of May 15, 2026. Recent financing included a registered direct sale of 5,263,156 shares and accompanying warrants at $1.90 per unit, generating net proceeds of $9.3M.
Annovis Bio, Inc. is conducting a registered direct offering of 5,263,156 shares of common stock paired with warrants to purchase up to 5,263,156 additional shares. Each share is sold together with a warrant at a combined public offering price of $1.90 per pair.
The warrants will be first exercisable six months after issuance, expire five and one-half years from issuance, and have an exercise price of $2.50 per share. The company expects net proceeds of approximately $9.175 million, which it plans to use to continue Phase 3 development of buntanetap for Alzheimer’s disease and for working capital and general corporate purposes. Shares outstanding were 29,269,237 as of April 8, 2026, and the expected post-offering outstanding share count is 34,532,393 assuming full sale of this offering.
Annovis Bio (ANVS) launched a registered direct primary offering of 1,670,732 shares of common stock at $2.05 per share, with gross proceeds of $3,425,001. The company estimates net proceeds of approximately $3.3 million, and the fee table shows proceeds to the company of $3,339,251 before expenses and fees. Annovis is also issuing placement agent warrants to purchase up to 83,537 shares at an exercise price of $2.5625 per share, exercisable for five years, and this supplement covers the common stock issuable upon their exercise.
H.C. Wainwright & Co. acted as exclusive placement agent. A 7.0% cash fee applies only to 597,561 shares, totaling $85,750. Shares outstanding were 24,443,938 as of October 24, 2025, and are expected to be 26,114,670 after the offering. Annovis plans to use proceeds to advance a Phase 3 study of Buntanetap in Alzheimer’s disease and for working capital and general corporate purposes.
Annovis Bio (ANVS) launched a registered direct offering of 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999, each pre-funded warrant carrying a $0.0001 exercise price. The company is also registering placement agent warrants to purchase up to 200,000 shares at $2.20.
Gross proceeds are listed at $5,999,915 with a 7.0% placement fee; estimated net proceeds are approximately $5,515,000, to fund a Phase 3 Alzheimer’s study of Buntanetap and for working capital. The pre-funded warrants are immediately exercisable and include a beneficial ownership cap of 4.99%, or 9.99% at the purchaser’s election. Shares outstanding would be 24,152,377 after the offering, assuming full exercise of pre-funded warrants and no exercise of placement agent warrants, based on 20,152,377 shares as of October 10, 2025.
H.C. Wainwright & Co. served as exclusive placement agent. Annovis notes prior clinical results in Parkinson’s and Alzheimer’s studies and alignment with the FDA on an AD Phase 3 program while highlighting ongoing capital needs.